Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH)

X

Xi'an Jiaotong University

Status

Begins enrollment in 6 months

Conditions

Cardiomyopathies

Treatments

Biological: Diagnosis of LVNC
Biological: Diagnosis of DCM
Biological: Diagnosis of ARVC
Biological: Diagnosis of RCM
Biological: Diagnosis of NDLVC
Biological: Diagnosis of HCM

Study type

Observational

Funder types

Other

Identifiers

NCT06352320
XJTU1AF2023LSK-533

Details and patient eligibility

About

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Full description

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Enrollment

500 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 years old.
  • The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
  • Patients or their families agreed to participate in the study and authorized informed consent.

Exclusion criteria

  • Incomplete clinical data.
  • Do not agree to the inclusion or refuse to authorize the informed consent.

Trial design

500 participants in 6 patient groups

HCM group
Description:
Patients were diagnosed with HCM.
Treatment:
Biological: Diagnosis of HCM
DCM group
Description:
Patients were diagnosed with DCM.
Treatment:
Biological: Diagnosis of DCM
ARVC group
Description:
Patients were diagnosed with ARVC.
Treatment:
Biological: Diagnosis of ARVC
NDLVC group
Description:
Patients were diagnosed with NDLVC.
Treatment:
Biological: Diagnosis of NDLVC
RCM group
Description:
Patients were diagnosed with RCM.
Treatment:
Biological: Diagnosis of RCM
LVNC group
Description:
Patients were diagnosed with LNVC.
Treatment:
Biological: Diagnosis of LVNC

Trial contacts and locations

1

Loading...

Central trial contact

Guoliang Li; Yang Yan

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems